Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

REmote Virtual Inspiration: Vitality and Energy (REVIVE)

4 sierpnia 2026 zaktualizowane przez: Rebecca Lee, Arizona State University

Improving Cardiometabolic Health With Meditative Movement in Mobility Impaired Women

REVIVE is a randomized controlled trial designed to evaluate the effects of a remotely delivered seated Tai Chi/Qigong (TCQ) intervention on cardiometabolic health, stress, sleep, and psychological well-being among women with mobility impairments.

Women with mobility impairments experience higher rates of obesity, cardiometabolic disease, chronic stress, sleep disturbances, and mental health concerns compared with women without disabilities. Limited access to accessible physical activity programs and barriers to participation in traditional exercise interventions contribute to these health disparities. Tai Chi and Qigong are gentle mind-body practices that may improve physical and psychological health through movement, breathing, and mindfulness techniques and can be adapted for individuals with limited mobility.

Participants will be randomized to either a seated Tai Chi/Qigong intervention or a health education video control condition. During the 12-week intervention phase, participants will receive daily video-based content delivered remotely. Participants assigned to the Tai Chi/Qigong group will engage in seated meditative movement practices, while participants assigned to the control group will receive health and wellness education videos unrelated to physical activity or nutrition behavior change.

Outcomes will be assessed remotely at baseline, post-intervention, and follow-up. Primary outcomes include waist circumference and indicators of physiological stress regulation, including heart rate variability and salivary cortisol. Secondary outcomes include perceived stress, emotion regulation, depression, anxiety, emotional eating, sleep quality, and sleep disturbance. Additional measures collected through wearable technology, sleep diaries, questionnaires, and biological samples will be used to examine potential behavioral, psychological, and physiological mechanisms underlying intervention effects.

The findings from this study will contribute to the development of accessible, scalable, and evidence-based health promotion interventions designed to improve cardiometabolic health and overall well-being among women with mobility impairments.

Przegląd badań

Status

Rekrutacyjny

Warunki

Interwencja / Leczenie

Szczegółowy opis

The REVIVE study is a fully remote, two-arm randomized controlled trial designed to test a seated Tai Chi/Qigong intervention adapted for women with mobility impairments. The study addresses the need for accessible, home-based interventions that can support health and well-being among individuals who may experience barriers to traditional in-person physical activity programs.

Participants complete all study activities from home over approximately 30 weeks. After screening and baseline procedures, participants are randomized to one of two study conditions: a seated Tai Chi/Qigong intervention or a health education video control condition. The study includes a baseline assessment period, a 12-week guided intervention phase, a post-intervention assessment period, a 12-week unprompted phase, and a final follow-up assessment period.

During the guided intervention phase, participants receive daily video-based content. Participants assigned to the Tai Chi/Qigong condition receive seated practice videos that include gentle movements, breathing exercises, mindfulness, relaxation, body awareness, and meditative movement practices. Videos include shorter and longer options to support flexibility and accommodate participant preferences, and schedules.

Participants assigned to the health education video control condition receive daily wellness education videos delivered with the same frequency and format. Control videos address general wellness topics but do not include meditative movement, structured exercise instruction, or physical activity behavior change strategies.

Study assessments are conducted remotely using online surveys, wearable technology, sleep diaries, remote measurement procedures, and at-home saliva collection. Study staff provide training and online support to help participants complete study activities and assessments from home.

REVIVE will evaluate whether a remotely delivered, seated Tai Chi/Qigong intervention adapted for women with mobility impairments can improve cardiometabolic and stress-related health outcomes. The study will also examine potential biological, psychological, and behavioral pathways that may explain intervention effects. Findings may inform future clinical and community-based programs designed to improve health and quality of life among women with mobility impairments.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

280

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

  • Stany Zjednoczone
    • Arizona
      • Phoenix, Arizona, Stany Zjednoczone, 85004
        • Rekrutacyjny
        • Arizona State University
        • Kontakt:
        • Główny śledczy:
          • Rebecca E Lee, PhD

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Self-identify as a woman.
  • Age 35-64 years.
  • Mobility impairment lasting at least 1 year.
  • Regular use of a mobility aid (e.g., wheelchair, scooter, walker, cane, crutches, or other assistive device).
  • Community dwelling.
  • Able to demonstrate sufficient upper-extremity mobility to participate in seated Tai Chi/Qigong activities.
  • Access to a smartphone, tablet, or computer with internet access.
  • Willing to wear a study-provided wearable device and complete study assessments.
  • Reside in the United States.
  • Waist circumference ≥ 33 inches (84 cm).
  • Perceived Stress Scale (PSS) score ≥ 15.
  • Insomnia Severity Index (ISI) score ≥ 8.
  • Emotional eating indicated by a score < 3 on the Mindful Eating Questionnaire (MEQ) Emotional Response subscale.
  • Able to understand written and spoken English.
  • Able to provide informed consent.
  • Able to provide healthcare provider approval for participation.

Exclusion Criteria:

  • Medical conditions that would make participation unsafe, as determined during screening.
  • Inability to safely perform seated upper-body movements.
  • Current participation in a structured Tai Chi, Qigong, or similar meditative movement program.
  • Pregnancy, lactation, or plans to become pregnant during the study period.
  • Cognitive, visual, auditory, or other impairments that would preclude completion of study procedures.
  • Implanted cardiac devices or implanted electronic devices that interfere with physiologic measurements.
  • Severe arrhythmia, left ventricular assist device (LVAD), or other conditions that interfere with heart rate variability assessment.
  • Use of sleep medications three or more times per week.
  • Medical conditions or medications that substantially affect autonomic nervous system activity, sleep, or stress-related outcomes.
  • Uncontrolled cardiovascular, neurological, psychiatric, or other serious medical conditions that would preclude safe participation.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Accesible Tai Chi/Qigong
Participants receive a 12-week remotely delivered seated Tai Chi/Qigong intervention consisting of daily video-based meditative movement sessions adapted for women with mobility impairments.
Behawioralne: Accesible Tai Chi/Qigong (TCQ)
A remotely delivered seated Tai Chi/Qigong intervention designed for women with mobility impairments. Participants receive daily video-based sessions that incorporate seated meditative movement, breathing exercises, mindfulness, relaxation techniques, and body awareness practices. Short and long session options are available throughout the 12-week intervention period.
Aktywny komparator: Health Education Videos (HEV)
Participants receive a 12-week remotely delivered health education program consisting of daily video-based wellness education content on a variety of health-related topics.
Behawioralne: Health Education Videos (HEV)
A remotely delivered health education program consisting of daily video-based wellness education content provided over 12 weeks. Topics include healthy aging, preventive healthcare, chronic disease awareness, communication with healthcare providers, and other general wellness topics. The program does not include Tai Chi, Qigong, exercise instruction, or physical activity behavior change content.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Waist Circumference (cm)
Ramy czasowe: Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)
Change in waist circumference measured in centimeters using a standardized Zoom-guided measurement protocol. Waist circumference is used as an indicator of abdominal adiposity and cardiometabolic risk.
Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)
High-Frequency Heart Rate Variability (HF Power)
Ramy czasowe: Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
Change in nocturnal high-frequency (HF) heart rate variability power measured using the Oura Ring. Higher HF power indicates greater parasympathetic nervous system activity and autonomic balance. HF power is the primary heart rate variability parameter used to assess physiological stress regulation.
Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
Diurnal Salivary Cortisol Area Under the Curve (AUCg)
Ramy czasowe: Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)
Change in diurnal salivary cortisol area under the curve with respect to ground (AUCg), calculated from saliva samples collected over two days with three samples per day. Lower AUCg values indicate reduced hypothalamic-pituitary-adrenal (HPA) axis activation and biological stress.
Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Perceived Stress Scale (PSS-10) Total Score
Ramy czasowe: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Change in perceived stress measured using the 10-item Perceived Stress Scale (PSS-10). Scores range from 0 to 40, with higher scores indicating greater perceived stress. The primary reported value will be the total score.
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Emotion Regulation Questionnaire (ERQ) Cognitive Reappraisal Score
Ramy czasowe: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Change in cognitive reappraisal measured using the Emotion Regulation Questionnaire (ERQ). Scores range from 1 to 7, with higher scores indicating greater use of cognitive reappraisal strategies.
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Center for Epidemiologic Studies Depression Scale (CES-D-10) Total Score
Ramy czasowe: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Change in depressive symptoms measured using the 10-item CES-D. Scores range from 0 to 30, with higher scores indicating greater depressive symptom severity.
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Generalized Anxiety Disorder-7 (GAD-7) Total Score
Ramy czasowe: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Change in anxiety symptoms measured using the Generalized Anxiety Disorder-7 (GAD-7). Scores range from 0 to 21, with higher scores indicating greater anxiety severity.
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Insomnia Severity Index (ISI) Total Score
Ramy czasowe: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Change in insomnia symptoms measured by the Insomnia Severity Index (ISI). The ISI is a 7-item self-report questionnaire with total scores ranging from 0 to 28. Higher scores indicate greater insomnia severity.
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Sleep Efficiency Measured by Oura Ring
Ramy czasowe: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Change in sleep efficiency (%) measured objectively using the Oura Ring wearable device.
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Sleep Diary
Ramy czasowe: Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
Average sleep outcomes derived from the 14-day Consensus Sleep Diary completed during each assessment period.
Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
Mindful Eating Questionnaire (MEQ) Emotional Eating Subscale Score
Ramy czasowe: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Change in emotional eating measured using the Emotional Eating subscale of the Mindful Eating Questionnaire (MEQ). Subscale scores range from 1 to 4, with higher scores indicating lower levels of emotional eating and more mindful eating behaviors.
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
PROMIS Sleep Disturbance Short Form T-Score
Ramy czasowe: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Change in sleep disturbance measured using the PROMIS Sleep Disturbance Short Form. Raw scores range from 8 to 40 and are converted to standardized T-scores, with higher T-scores indicating greater sleep disturbance.
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
Check And Line Questionnaire (CALQ)
Ramy czasowe: Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
Average daily minutes of self-reported physical activity will be measured using the Check and Line Questionnaire (CALQ) over the 14-day assessment period. Participants will report total daily or weekly minutes of light, moderate, and vigorous physical activity, or any combination of these, rounded to the nearest 15-minute increment.
Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Arizona State University

Współpracownicy

National Institute on Aging (NIA)

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 września 2026

Zakończenie podstawowe (Szacowany)

30 sierpnia 2030

Ukończenie studiów (Szacowany)

30 sierpnia 2030

Daty rejestracji na studia

Pierwszy przesłany

17 czerwca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

23 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

30 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

5 sierpnia 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

4 sierpnia 2026

Ostatnia weryfikacja

1 sierpnia 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Inne numery identyfikacyjne badania

  • STUDY00023587
  • R01AG088032-01A1 (Grant/umowa NIH USA)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Data collected as part of this project will be de-identified and made available on public websites that may be shared with investigators working under an institution with a Federal Wide Assurance (FWA). As there is no specific data sharing repository for the funding agency, the investigators will identify possible other repositories that may be appropriate to use. For whatever NIH-funded repository is advised to be used, the investigators acknowledge that this repository will have policies and procedures in place that will provide data access to qualified researchers, consistent with NIH data sharing policies and applicable laws and regulations. Data will be deposited to the repository as soon as possible but no later than within one year of the completion of the funded project period for the parent award.

Ramy czasowe udostępniania IPD

Study protocol and statistical Analysis Plan will be available by December 2030 with no end date.

Kryteria dostępu do udostępniania IPD

De-identified individual participant data underlying published results may be made available to qualified researchers upon reasonable request. Requests will be reviewed by the study investigators and Arizona State University to ensure participant confidentiality, compliance with institutional policies, and appropriate scientific use. Data use agreements may be required prior to data release.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ICF

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj